Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

Starting soon · Phase 2/Phase 3

Conditions studied: Cancer

In brief

This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.

Key facts

Study ID

NCT06800092

Run by

The University of Texas Medical Branch, Galveston

People needed

30

Starts

2027-06-15

Expected to finish

2030-06-01

Last updated by the study team

2026-05-11

Who can join

Age: 30 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female
• Ages 30 - 50 years
• Self-reported menses occurrence within past 12 months
• Diagnosis of ER+/HER2- breast cancer
• Willing and able to comply with study procedures
• Willing and able to provide consent

You may not qualify if…

• Untreated thyroid disorder
• Untreated diabetes
• BMI >30
• Current treatment with metformin
• Diagnosed neuromuscular disease
• Diagnosed neurovascular disease
• Prior history of cognitive impairment
• Prior history of chemotherapy treatment
• HIV, Hepatitis B or Hepatitis C
• Systolic blood pressure <90 or >170, diastolic blood pressure <50 or >110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (>90/50 and <170/110)
• Use of alpha blockers in the past 2 weeks
• Use of PDE5 inhibitors in the past 2 weeks
• Use of nitrates
• Subjects with MRI incompatible devices
• Subjects with severe claustrophobia
• Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation

Where it is running

• The University of Texas Medical Branch — Galveston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.